Deskside with Dr. Dan
FDA approves pralsetinib for lung cancer with RET gene fusions
Dr. Dan, Chief Medical Officer at Gryt Health breaks down the approval of pralsetinib by the FDA for lung cancer patients with RET gene fusions.
Gryt Health
August 4, 2022
